Cover Image

Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells

Abstract Anti‐PD‐1/PD‐L1 immunotherapy could offer an alternative to traditional chemo‐ and/or radiotherapy to treat pediatric cancer patients. To unveil the potential benefit of this new therapeutic approach, the prevalence of PD‐L1 and other relevant immune markers using quantitative digital image...

Full description

Saved in:

Bibliographic Details
Main Authors:	Manuel A Silva (Author), Nicolas Triltsch (Author), Simon Leis (Author), Ivan Kanchev (Author), Tze Heng Tan (Author), Benjamine Van Peel (Author), Marian Van Kerckhoven (Author), Vanessa Deschoolmeester (Author), Johannes Zimmermann (Author)
Format:	Book
Published:	Wiley, 2020-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022)

The function and regulation of PD-L1 in immunotherapy
by: Libin Guo, et al.
Published: (2017)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019)

The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases
by: Dominika Katarzyna Madras, et al.
Published: (2020)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
by: Xi Chen, et al.
Published: (2020)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
by: Hashem O. Alsaab, et al.
Published: (2017)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
by: Luisa Chocarro de Erauso, et al.
Published: (2020)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
by: Fabian Krutzek, et al.
Published: (2022)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
by: van Wijk Femke, et al.
Published: (2011)

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
by: Ge Y, et al.
Published: (2022)

Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress
by: Ziwei Li, et al.
Published: (2024)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
by: Matyas Meggyes, et al.
Published: (2019)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022)

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients
by: Takeru Kashiwada, et al.
Published: (2024)

Investigation of the PD-1/PD-L1 Expression in the Lesional Skins of Patients with Psoriasis
by: Selma Emre, et al.
Published: (2023)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
by: Vishakha Singh, et al.
Published: (2021)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
by: Zsófia Király, et al.
Published: (2022)

Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer
by: Chengpei Zhu, et al.
Published: (2024)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
by: Keyu Yuan, et al.
Published: (2022)

PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017)

Meningiomas and the tumor microenvironment: expression of PD-L1 and expression of PD-L1 and interferon-gamma in the prognosis
by: Gunter Gerson, et al.

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021)

A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
by: Yongming Chen, et al.
Published: (2024)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023)

The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
by: Aleksandra S. Paderina, et al.
Published: (2024)

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules
by: Marialuigia Fantacuzzi, et al.
Published: (2024)

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
by: Nan Zhang, et al.
Published: (2024)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
by: Yuqian Feng, et al.
Published: (2021)